Tag: PILL.C
-
![Canntab Therapeutics (PILL.C): a pressing investment opportunity – Today’s Idea]()
Canntab Therapeutics (PILL.C): a pressing investment opportunity – Today’s Idea
Canntab Therapeutics (PILL.C) has been around the block and then some. The Ontario-based pharmaceutical answer to medicinal cannabis, has pioneered a patented process to turn CBD, THC and terpene and other cannabinoid distillates into hard-pressed pills that reliably deliver accurately measured dosages with optimal bioavailability. The company’s instant release and extended-release formulations round out a…
-
![Canntab Therapeutics (PILL.C) Enters Agreement with 36Eight Technologies]()
Canntab Therapeutics (PILL.C) Enters Agreement with 36Eight Technologies
Canntab Therapeutics (PILL.C) announced today that it has reached an agreement with 36Eight Technologies (“36Eight”), whereby “36Eight” will list, market, and support all of Canntab’s market-exclusive and patent-protected solid and exact dose products. “This is an exciting opportunity for Canntab, as we believe 36Eight’s unique and valuable complementary platform will support our ability to provide…
-
![As Australia opens to cannabis, Canntab’s (PILL.C) tech might just claim the box seat]()
As Australia opens to cannabis, Canntab’s (PILL.C) tech might just claim the box seat
News this week that Canntab Therapeutics (PILL.C) received an Australian patent for their hard-pressed cannabis pill tech, to match those received earlier in North America, didn’t launch the stock into space. That’s understandable, to be honest, as North American investors have taken an eye off the island continent and its slow roll to weed legalization…
-
![Canntab Therapeutics (PILL.C) racks up revenue as CBD caplets shipped to Medipharm (LABS.T)]()
Canntab Therapeutics (PILL.C) racks up revenue as CBD caplets shipped to Medipharm (LABS.T)
Cannabis hard tablet IP holder Canntab Therapeutics (PILL.C) continues to send product to market, announcing Wednesday they’ve fulfilled 80% of their contract with Medipharm Labs (LABS.T), bringing in another half million dollars in revenue toward the $1.3 million deal announced last June. Orders under the agreement are a mix of Canntab’s proprietary instant release tablets…
-
Canntab (PILL.C) yeets another patent for hard-pressed, long release cannabis pills
I’ve made no secret of the fact that the Canadian cannabis market frequently annoys the hell out of me. What I want is for it to be a mature space that more and more adults are making use of, and that is free to innovate, free to be excellent, free to market itself properly, and…
-
![Canntab Therapeutics (PILL.C): The Canadian weed sector is struggling, but new consumer products have room to scale]()
Canntab Therapeutics (PILL.C): The Canadian weed sector is struggling, but new consumer products have room to scale
If we’re honest about it – if we’re REALLY honest about it – Canada has fumbled its advantage in the cannabis sector. First to market, first to raise hundreds of millions in financing, first to legalize, first to recreationalize (not a word but I’m on a roll), and it’s all really been for naught. In…
-
Canntab Therapeutics’ (PILL.C) bursts out of the starting blocks with $1.3 million sale
PILL is developing solid oral dose formulations of cannabis with a product line of cannabinoid (THC & CBD) and terpenoid blends in multiple doses and timed-release combinations
